A systematic review of possible interactions for herbal medicines and dietary supplements used concomitantly with disease‐modifying or symptom‐alleviating multiple sclerosis drugs

2021 ◽  
Author(s):  
Malene J. Petersen ◽  
Sofie O. Bergien ◽  
Dan Staerk
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Dietary Supplements ◽  
Herbal Medicines ◽  
Disease Modifying

scholarly journals Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review

2018 ◽  
Vol 26 ◽  
pp. 124-156 ◽  
Author(s):  
Majid Gasim ◽  
Charles N. Bernstein ◽  
Lesley A. Graff ◽  
Scott B. Patten ◽  
Renee El-Gabalawy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Disease Modifying Therapies ◽  
Disease Modifying

scholarly journals Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review

PLoS ONE ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. e0231722 ◽  
Author(s):  
Rosa C. Lucchetta ◽  
Letícia P. Leonart ◽  
Marcus V. M. Gonçalves ◽  
Jefferson Becker ◽  
Roberto Pontarolo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Clinical Studies ◽  
Disease Modifying Therapies ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis

Neurology ◽  
2020 ◽  
Vol 94 (22) ◽  
pp. e2373-e2383 ◽  
Author(s):  
Nils C. Landmeyer ◽  
Paul-Christian Bürkner ◽  
Heinz Wiendl ◽  
Tobias Ruck ◽  
Hans-Peter Hartung ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Cognitive Impairment ◽  
Test Performance ◽  
Meta Analysis ◽  
Cognitive Test ◽  
Current Evidence ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Cognitive Test Performance

ObjectiveDisease-modifying treatments (DMTs) are the gold standard for slowing disability progression in multiple sclerosis (MS), but their effects on cognitive impairment, a key symptom of the disease, are mostly unknown. We conducted a systematic review and meta-analysis to evaluate the differential effects of DMTs on cognitive test performance in relapsing-remitting MS (RRMS).MethodsPubMed, Scopus, and Cochrane Library were searched for studies reporting longitudinal cognitive performance data related to all major DMTs. The standardized mean difference (Hedges g) between baseline and follow-up cognitive assessment was used as the main effect size measure.ResultsForty-four studies, including 55 distinct MS patient samples, were found eligible for the systematic review. Twenty-five studies were related to platform therapies (mainly β-interferon [n = 17] and glatiramer acetate [n = 4]), whereas 22 studies were related to escalation therapies (mainly natalizumab [n = 14] and fingolimod [n = 6]). Reported data were mostly confined to the cognitive domain processing speed. A meta-analysis including 41 studies and 7,131 patients revealed a small to moderate positive effect on cognitive test performance of DMTs in general (g = 0.27, 95% confidence interval [CI] = [0.21–0.33]), but no statistically significant differences between platform (g = 0.27, 95% CI = [0.18–0.35]) and escalation therapies (g = 0.28, 95% CI = [0.19–0.37]) or between any single DMT and β-interferon.ConclusionsDMTs are effective in improving cognitive test performance in RRMS, but a treatment escalation mainly to amend cognition is not supported by the current evidence. Given the multitude of DMTs and their widespread use, the available data regarding differential treatment effects on cognitive impairment are remarkably scant. Clinical drug trials that use more extensive cognitive outcome measures are urgently needed.

Disease-Modifying Drugs for Multiple Sclerosis in Pregnancy: A Systematic Review (P06.188)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P06.188-P06.188
Author(s):  
E. Lu ◽  
B. W. Wang ◽  
C. Guimond ◽  
A. Synnes ◽  
D. Sadovnick ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
In Pregnancy

scholarly journals Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review

Neurology ◽  
2013 ◽  
Vol 80 (11) ◽  
pp. 1068-1069 ◽  
Author(s):  
J. A. Charles ◽  
H. Tremlett ◽  
E. Lu ◽  
C. Guimond ◽  
A. D. Sadovnick
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document